Using innovation survey data to evaluate R&D policy in Flanders Additionality research Kris Aerts Dirk Czarnitzki K.U.Leuven K.U.Leuven Steunpunt O&O Statistieken Steunpunt O&O StatistiekenBelgium
2 Contents 1. Introduction 2. Literature review 3. Evaluation of the Flemish R&D policy 4. Conclusion
1. Introduction
4 R&D in Europe Barcelona target: 2010: 3% of GDP EU R&D 2010: 3% of GDP EU R&D 1/3 public 2/3 private funding But: private R&D ~ public good positive externalities! subsidies!
5 Subsidies: economic dilemma Crowding out effect? public grants - private investment Empirical analysis relationship between R&D subsidies and R&D activities treatment effects analysis Flanders
2. Literature review
7 Literature review ► Blank & Stigler (1957) ► David et al. (2000) ► Klette et al. (2000) Inconclusive BUT: Selection bias “picking the winner” strategy
8 Selection bias REAL QUESTION: “How much would the recipients have invested if they had not participated in a public policy scheme?” Matching estimator 1.Probit model on participation dummy 2.Regression of R&D activity (including selection correction: accounting for different propensities of firms to be publicly funded) Selection model
9 Recent research ► ► Wallsten (2000) – US ► ► Lach (2002) – Israel ► ► Czarnitzki et al. (2001, 2002, 2003) & Hussinger (2003) – Germany ► ► Duguet (2004) – France ► ► González et al. (2004) – Spain Majority of recent studies: complimentary effects but no complete rejection of crowding out effects ► ► Holemans & Sleuwaegen (1988), Meeusen & Janssens (2001) & Suetens (2002) – R&D-performing firms in Belgium (not controlling for selection bias)
3. Evaluation of the Flemish R&D policy
11 Tackle problem of selection bias Matching estimator Selection model
12 Matching estimator “What would a treated firm with given characteristics have done if it had not been treated?” (treatment = receipt of a subsidy for R&D) Variation on Heckman’s selection model well suited for cross-sectional data no assumption on functional form or distribution only controlling for observed heterogeneity among treated and non treated firms
13 Matching estimator (2) Average treatment effect on treated firms: Outcome variable: R&D spending Status: S=1 treated S=0 not treated Potential outcome if treated group would not have been treated Directly observable?
14 Matching estimator (3) Problem: E(Y C |S=1) = ? Rubin (1977): conditional independence assumption Participation and potential outcome are independent for individuals with the same set of exogenous characteristics XTHUS:
15 Matching estimator (4) Best matching: more than one matching argument BUT: Curse of dimensionality Solution: Propensity score Rosenbaum/Rubin (1983): probit model on receipt of subsidies Lechner (1998): hybrid matching include additional variables
16 Matching protocol Specify and estimate probit model to obtain propensity scores Restrict sample to common support (remove outliers) Choose one observation from sub sample of treated firms and delete it from that pool Calculate Mahalanobis distance between this firm and all non-subsidized firms in order to find most similar control observation Select observation with minimum distance from remaining sample (selected controls are not deleted from the control group) Repeat steps 3 to 5 for all observations on subsidized firms The average effect on the treated = mean difference of matched samples: Sampling with replacement ordinary t-statistic on mean differences is biased (neglects appearance of repeated observations) correct standard errors: Lechner (2001) estimator for an asymptotic approximation of the standard errors
17 Selection model Effect of the treatment on the treated firms: BUT we need an instrumental variable!!! effect on probability to receive funding but no effect on R&D and innovative activity
18 Dataset ► Flemish companies ► Sources: Third Community Innovation Survey (CIS III) observations – 179 subsidy recipients ICAROS database IWT IWT= main company funding institution in Flanders Patent data from European Patent Office (EPO) data on all patent applications since 1978
19 Variables ► Receipt of subsides: ► Receipt of subsides: dummy variable (local government, national government and EU) ► Outcome variables: R&D: R&D: R&D expenditure at firm level in 2000 R&Dint: R&Dint: R&D expenditure / turnover *100 (very skewed distribution also logarithmic transformation scales) Patent/EMP: Patent/EMP: patent applications in 2000 per employee D(Patent>0): D(Patent>0): dummy variable for patenting firms
20 Variables ► Control variables (1): nprj: nprj: number of projects applied for in the past Control for previous funding history lnEmp: lnEmp: number of employees in 1998 ln smoothens variable export : export : exports/turnover Degree of international competition group: group: part of group foreign: foreign: owned by foreign parent company
21 Variables ► Control variables (2): PStock/Emp: PStock/Emp: firm’s patent stock per employee control for previous (successful) R&D activities per employee: avoid multicollinearity with firm size 1979 to 1997: past innovation activities Depreciation rate of knowledge: 0,15 e.g. Hall (1990) Patent Stock of firm i in period t Patent applications filed at EPO of firm i in period t
22 Descriptive statistics subsidized firmspotential control group p-value of two- sided t-test on mean equality N 1 = 179N 0 = 596 MeanStd. Dev.MeanStd. Dev. NPRJ p = lnEMP p < GROUP p = FOREIGN p = EXPORT p < PSTOCK/EMP p = R&D p = R&DINT p < lnR&D p < lnR&DINT p < D(PATENT>0) p = PATENT/EMP p = Differences: treatment or other characteristics? Matching technique Observations without common support are dropped => 174 firms
23 Matching procedure Probit estimation on the receipt of subsidies CoefficientStd. err. NPRJ lnEMP0.184***0.047 PSTOCK/EMP0.106***0.038 GROUP FOREIGN-0.337**0.142 EXPORT0.725***0.171 Constant term-1.926***0.319 Test on joint significance on industry dummies 2 (11) = Log-Likelihood Pseudo R-squared Number of obs.774 *** (**, *) significance level of 1% (5, 10%) The regression includes 11 industry dummies CoefficientStd. err *** * * *** ***0.437 2 (11) =
24 Matching procedure Propensity score (+ size) select nearest neighbour Kernel density estimates BEFORE matching AFTER matching propensity score size
25 Matching results subsidized firmspotential control group p-value of two-sided t- test on mean equality N 1 = 174N 0 = 174 MeanStd. Dev.MeanStd. Dev. NPRJ p = lnEMP p = PSTOCK/EMP p = GROUP p = FOREIGN p = EXPORT p = Propensity score p = R&D p = lnR&D p = R&DINT p = lnR&DINT p = D(PATENT>0) p = PATENT/EMP p = 0.647
26 Selection model N(obs)Mean differenceStd. Dev. R&D ***1.909 R&DInt ***1.971 lnR&D ***0.638 lnR&DInt ***0.258 *** (**, *) significance level of 1% (5, 10%) Instrumental variable NPRJ valid?
4. Conclusion
28 Conclusion ► Matching estimator ► Selection model No full crowding out
29 Future research ► Time series analysis: robustness of analysis + lag variables ► Amount of subsidies ► Relationship with output variables productivity / performance ► Including dataset on all subsidies applied for at IWT (Flemish government)
30 Evaluation of the usefulness of the CIS in this domain rich dataset, especially when combined with other data sources no amounts of funding; only dummy firm-level data versus project-level data link with output? link with other variables? (behavioral additionality)
31 Evolution of CIS question in this domain: Evolution of CIS question in this domain: CIS III Did your company receive financial government support for innovative activities between 1998 and 2000? Belgian governments: OYES: Which institution(s)? ONO The European Union: OYES: FP4 or FP5? O YES O NO ONO
32 Evolution of CIS question in this domain: Evolution of CIS question in this domain: CIS IV Did your company receive any government support for innovative activities between 2002 and 2004? Local or regional governments O YES O NO Federal government O YES O NO The EU O YES: O NO FP5 or FP6? O YES O NO 3xNO: GO to next question Was (part of) this government support granted for activities in which your company was involved in a collaboration agreement? O YES O NO: GO to next question Was a university or public research institution involved in (one of) these collaboration agreement(s)? O YES O NO
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? QUESTIONS?